What Has Been the Growth Trajectory for the Inhalation Anesthesia Market in Recent Years?
The inhalation anesthesia market has seen considerable growth due to a variety of factors.
• The market for inhalation anesthesia has been experiencing robust growth in recent years. The market size is projected to expand from $1.54 billion in 2024 to $1.65 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%.
This growth in the past years is largely due to the increased number of surgeries requiring anesthesia, growth of the elderly population, advancement in inhalation anesthetics, the proliferation of ambulatory surgical centers, and the rising incidence of chronic diseases such as heart disease and cancer.
How Does the Forecast Look for the Inhalation Anesthesia Market?
The inhalation anesthesia market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of inhalation anesthesia is anticipated to witness substantial growth in the forthcoming years, escalating to $2.34 billion in 2029 with a 9.1% compound annual growth rate (CAGR).
This growth during the forecast period can be related to factors such as the increasing demand for minimally invasive surgeries, escalating global healthcare spending, growing surgical procedures in emerging markets, the use of inhalation anesthesia in veterinary medicine, and increased government funding for research and development of innovative inhalation anesthetics. The forecast period also sees significant trends such as technological advancements in anesthesia delivery systems, creation of inhalation anesthesia devices for children's use, a shift in preference towards sevoflurane and desflurane, the emphasis on environmentally-friendly anesthetic agents, and the incorporation of monitoring technologies within anesthesia delivery.
What Main Forces Are Fueling Expansion In The Inhalation Anesthesia Market?
The forthcoming rise in the elderly population is predicted to fuel inhalation anesthesia's growth. This segment's progression is being expedited due to the older demographic's predisposition to chronic diseases and degenerative conditions, resulting in an increased need for surgeries and medical treatments. Furthermore, the growing older population, vulnerable to various health issues such as cardiovascular, neurologic, respiratory, and degenerative diseases, acts as a driving force propelling the market growth. Intravenous anesthesia administration tends to pose difficulties in elderly patients due to punctured blood vessels and compliance issues. For example, the World Health Organization, based in Switzerland, reported in October 2022 that the global populace of individuals aged 60 and over is estimated to reach 1.4 billion by 2022, up from 1 billion in 2020. Additionally, by 2030, one in six individuals worldwide will be over the age of 60. Thus, the escalating older population is foreseen to heighten the demand for inhalation anesthesia in the forecasted period.
What Are The Primary Segments In The Global Inhalation Anesthesia Market?
The inhalation anesthesia market covered in this report is segmented –
1) By Product: Sevoflurane, Desflurane, Isoflurane, Nitrous Oxide
2) By Application: Induction, Maintenance
3) By End User: Hospitals, Ambulatory Surgical Centers
Subsegments:
1) By Sevoflurane: Liquid Form, Gas Form
2) By Desflurane: Liquid Form, Gas Form
3) By Isoflurane: Liquid Form, Gas Form
4) By Nitrous Oxide: Medical-Grade Nitrous Oxide, Industrial-Grade Nitrous Oxide
Pre-Book The Inhalation Anesthesia Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Inhalation Anesthesia Market?
Many firms in the inhalation anesthesia sector are introducing revolutionary products such as Sedaconda globally to satisfy industry needs and enhance their market standing. Sedaconda is an inhalation sedation treatment administered with the Anaesthetic Conserving Device (ACD) and is sanctioned for usage in intensive care units. For example, Sedana Medical AB, a medical technology and pharmaceutical organization based in Sweden, launched Sedaconda (isoflurane) in the German market in February 2022. Sedaconda (isoflurane) is administered via a medical apparatus called the Sedaconda ACD (Anaesthetic Conserving Device) and is the only inhalation sedation treatment permitted for use in intensive care environments. After achieving the European DCP approval in July 2021, Sedaconda (isoflurane) has since been nationally approved in 14 nations.
Who Are the Key Players in the Inhalation Anesthesia Market?
Major companies operating in the inhalation anesthesia market include:
• Abbvie Inc.
• Baxter International Inc.
• Fresenius SE & Co. KGaA
• Halocarbon Products Corporation
• Hikma Pharmaceuticals PLC
• B. Braun Melsungen AG
• Lunan Pharmaceutical Group Co. Ltd.
• Maruishi Pharmaceutical Co. Ltd.
• Mylan N. V.
• Piramal Enterprises Ltd.
• Recipharm AB
• Sandoz International GmbH
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Wockhardt Ltd.
• AstraZeneca PLC
• C. H. Boehringer Sohn AG & Co. KG
• Bristol-Myers Squibb Company
• Eisai Co. Ltd.
• GlaxoSmithKline PLC
• Johnson & Johnson Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Sanofi S. A.
• Takeda Pharmaceutical Company Limited
• Teijin Pharma Limited
• UCB S. A.
• Zydus Lifesciences Limited
What Is The Most Dominant Region In The Inhalation Anesthesia Market?
North America was the largest region in the inhalation anesthesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalation anesthesia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
